GSK is poised to unveil groundbreaking advancements in oncology at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, reinforcing its unwavering commitment to revolutionize cancer care. With a focus on hematologic malignancies, gynecologic cancers, and various solid tumors, GSK will present findings from 25 abstracts, showcasing novel approaches that hold promise in transforming patient outcomes.
Central to these presentations are pivotal data from the DREAMM-8 and DREAMM-7 phase III trials, spotlighting the potential of belantamab mafodotin in multiple myeloma treatment post-first relapse. Specifically, results from the DREAMM-8 trial, evaluating belantamab mafodotin in combination with pomalidomide and dexamethasone (PomDex) versus bortezomib combined with PomDex, have been selected for inclusion in the ASCO press program. Subgroup analyses from the DREAMM-7 trial will also be highlighted, showcasing the efficacy of belantamab mafodotin plus bortezomib and dexamethasone (BorDex) compared to daratumumab plus BorDex.
Moreover, GSK will present encouraging new data from collaborative studies and alliances, potentially revolutionizing cancer care. Notably, updated results for dostarlimab in locally advanced mismatch repair deficient (dMMR) rectal cancer, from a collaboration with Memorial Sloan Kettering Cancer Center, will be showcased. Additionally, Hansoh Pharma’s oral presentation on their phase II study of HS-20093 in Chinese patients with relapsed or refractory osteosarcoma highlights GSK’s global efforts to expand treatment options.
Furthermore, updated results from a phase 0/II trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma underscore GSK’s commitment to addressing complex and treatment-resistant cancers. The promising median overall survival achieved with niraparib highlights its potential as a novel therapeutic option, leading to the acceleration of a phase III clinical trial supported by GSK.
GSK’s oncology portfolio encompasses innovative therapies targeting various pathways and mechanisms involved in cancer progression. From antibody-drug conjugates like belantamab mafodotin to programmed death receptor-1 (PD-1)-blocking antibodies like Jemperli, GSK is at the forefront of developing transformative treatments. Additionally, with recent approvals such as momelotinib for myelofibrosis, GSK continues to expand its impact in oncology, aiming to maximize patient survival and quality of life.
GSK’s dedication to advancing oncology through breakthroughs in immuno-oncology and tumor-cell targeting therapy underscores its pivotal role in reshaping the landscape of cancer treatment.